| |
| | ivpcare>About ivpcare>Press Room>Articles (Site not responding. Last check: 2007-10-29) |
 | | Ferring Pharmaceuticals announced today the launch of MENOPUR® (menotropins for injection, USP), a purified human menopausal gonadotropin (hMG) indicated for the development of multiple follicles and pregnancy in patients undergoing Assisted Reproductive Technology (ART), such as in vitro fertilization (IVF). |
 | | "Human menopausal gonadotropins are a critical component of many Assisted Reproductive Technology treatment protocols," said William Keye, M.D., Director, division of reproductive endocrinology and IVF programs, department of obstetrics and gynecology, William Beaumont Hospital. |
 | | MENOPUR® and REPRONEX ®, like all gonadotropins, are potent substances capable of causing mild to severe adverse reactions, including OHSS (incidence of 3.8% and 3.5%, respectively), with or without pulmonary or vascular complications, in women undergoing therapy for infertility. |
| www.ivpcare.com /about_ivpcare/press_room/articles/004.asp (645 words) |
|